CSPC Pharmaceutical Grants 9.46 Million Restricted Shares Under 2018 Award Scheme

CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.

CSPC Pharmaceutical Group has granted 9,462,000 restricted shares, equal to about 0.08% of its issued share capital, to 488 employees under its 2018 Share Award Scheme at nil consideration. The awards, priced against a market close of HK$9.71 per share on the grant date, are structured to vest in three equal tranches between January 2027 and January 2029, aligning long-term incentives with employee retention.

Vesting of each tranche is contingent on the achievement of defined annual performance targets through the financial year ending 31 December 2028, with the group using yearly performance appraisals to determine eligibility. A clawback mechanism allows the awards to lapse in cases such as dishonesty, serious misconduct or securities law offences, while the scheme still has 54,557,868 shares available for future grants, underscoring CSPC’s ongoing use of equity incentives to motivate staff without diluting control materially.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. It operates in the healthcare and drug manufacturing industry, focusing on the development, production and sale of pharmaceutical products for domestic and international markets.

Average Trading Volume: 114,863,932

Technical Sentiment Signal: Buy

Current Market Cap: HK$110.7B

Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.